If you developed cancer after taking the weight loss drug Belviq or Belviq XR, you could be owed significant monetary compensation.
According to the Center for Drug Evaluation and Research, Belviq was approved for use in 2012, and Eisai, the drug manufacturer, was required to conduct long-term studies into cardiac safety. However, after reviewing the results of the five-year study, the federal watchdog agency pulled the drug from the market. The study indicated an overall increase for cancer and a particularly elevated risk for pancreatic, lung, and colorectal cancer with extended use.
FDA Finds Weight Loss Drug Could Increase Risk of Certain Cancers
According to the FDA, Belviq (lorcaserin) and Belviq XR were withdrawn from the market after clinical trials indicated the weight loss medication could increase the risk of certain cancers, including: